Abstract: According to one embodiment, an automatic analysis apparatus includes a reagent storage and a reagent container arm. The reagent storage includes an outer circumferential table on which a plurality of reagent containers are loaded and an inner circumferential table located inside the outer circumferential table and on which a plurality of reagent containers are loaded. The reagent container arm conveys a reagent container to the inner circumferential table through between the reagent containers loaded on the outer circumferential table.

Abstract: A transport rack according to the present embodiment comprises a holder configured to hold a storage container that stores a sample or a reagent that is reacted with the sample, a first observation window configured to enable reading of identification information on the storage container, and a second observation window configured to enable observation of the sample or the reagent stored in the storage container.

Abstract: An automatic analysis device according to the present embodiment includes a processor. The processor calculates the liquid level height in a reaction tube, based on a scheduled dispensing amount of liquid to be dispensed into the reaction tube. The processor detects whether there is an abnormality in a dispensing operation in which liquid is dispensed into the reaction tube, based on a measured liquid level height in the reaction tube and a calculated liquid level height in the reaction tube.

Abstract: The present disclosure provides a therapy for diabetes that targets abnormal stem cells by HDAC inhibitors in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells by HDAC inhibitors in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells by HDAC inhibitors in combination with stem cell migration, in a subject in which abnormal stem cells have been detected.

Abstract: The present disclosure provides a diabetes mellitus therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a therapy for diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus, said therapy targeting abnormal stem cells. In one embodiment, the present disclosure provides a diagnosis of diabetes mellitus and/or a disease, a disorder and/or a symptom relating to diabetes mellitus or a risk of the same, said diagnosis using abnormal stem cells as an index. In one embodiment, the abnormal stem cells described in the present disclosure are abnormal hematopoietic stem cells. In one embodiment, CD106 is expressed in the abnormal stem cells described in the present disclosure at a level different from in normal cells.

Abstract: The present disclosure provides a therapy for diabetes that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides a therapy for diabetes and/or diabetes-related diseases and disorders and/or symptoms that targets abnormal stem cells in combination with stem cell migration. In one embodiment, the present disclosure provides diagnosis of diabetes and/or diabetes-related diseases and disorders and/or symptoms, or the risk thereof, using abnormal stem cell migration and/or residence as an indicator.

Abstract: Provided are a vehicle body assembling method and a vehicle body assembling device that are space-saving and economical. The vehicle body assembling method includes: a first holding step (S2) for holding a floor complete 1 by a first jig 9; a second holding step (S3) for holding a roof arch by a second jig; a jig connecting step (S4) for connecting the first jig and the second jig; a third holding step (S5) for holding side inner completes by the first jig and the second jig; and welding steps (S6 to S9) for forming an inner frame by welding.

Abstract: Provided are a vehicle body assembling method and a vehicle body assembling device that are space-saving and economical. The vehicle body assembling method includes: a first holding step (S2) for holding a floor complete 1 by a first jig 9; a second holding step (S3) for holding a roof arch by a second jig; a jig connecting step (S4) for connecting the first jig and the second jig; a third holding step (S5) for holding side inner completes by the first jig and the second jig; and welding steps (S6 to S9) for forming an inner frame by welding.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention concerns methods and compositions that employ peptides that target dorsal root ganglion (DRG) neurons. In particular, the peptides are used to target therapeutic agents, such as proteins, liposomes, or viral particles comprising therapeutic polynucleotides, to one or more peripheral neuropathies or neuropathic pain, for example. In particular cases, the peripheral neuropathies or neuropathic pain is caused directly or indirectly by DRG neuronopathy.

Abstract: The present invention is directed to compositions of an islet cell differentiation transcription factor polypeptide, or any of its homologs or orthologs, as a therapeutic agent for the treatment of diabetes, more specifically insulin-dependent diabetes. The methods and compositions of the present invention provide an increase in glucose tolerance, an increase in insulin, and/or an increase in insulin-producing cells in the host.

Abstract: An integrated circuit device is provided with a divided electrode pad which permits checking the electrical characteristics of individual circuit elements before assembly into a package housing. After testing, the divided electrode pad is connected by thermally bonding one end of a single lead wire or the like to the divided parts.